Latest News about LGND
Recent news which mentions LGND
7 Small-Cap Stocks for the Thinking Speculator
April 08, 2024
From InvestorPlace
Why Is Ligand Pharmaceuticals Stock Trading Higher Today?
February 27, 2024
From Benzinga
Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 27, 2024
From Benzinga
Norwegian Cruise Line Posts Strong Sales, Joins Hims & Hers Health, Sterling Infrastructure And Other Big Stocks Moving Higher On Tuesday
February 27, 2024
From Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
February 27, 2024
From Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
From Benzinga
Merck Highlights Data On New Vaccine, Compares 'Tolerability And Safety' To Pfizer's
November 28, 2023
From Benzinga
Ligand Pharma Updates Annual Guidance As It Spins Out Pelican Subsidiary
September 19, 2023
Tickers
LGND
From Benzinga
Why Are Novan Shares Nosediving Today?
July 17, 2023
From Benzinga
From InvestorPlace
Viking Therapeutics Outperforms Expectations: Analyst Increases Price Target Following Successful VK2809 Trial
May 16, 2023
From Benzinga
Earnings Scheduled For February 22, 2023
February 22, 2023
From Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
From Benzinga
From Benzinga
Roth Capital Maintains Buy Rating for Ligand Pharmaceuticals: Here's What You Need To Know
December 23, 2022
Tickers
LGND
From Benzinga
Tesla To $175? Here Are 10 Other Price Target Changes For Friday
December 23, 2022
From Benzinga
Some 'Transgenic Animal Platforms Are More Than Equal,' Analyst Initiating Coverage On OmniAb Says
December 16, 2022
From Benzinga
Best stock picks for 2023: Here are Wall Street analysts’ most heavily favored choices
December 13, 2022
From MarketWatch
These small-cap stocks might make you the most money in 2023, based on two important data points
December 07, 2022
From MarketWatch
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 02, 2022
From Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
From Benzinga
Janssen Scores Conditional Approval For Multiple Myeloma Treatment In Pretreated Patients
August 25, 2022
From Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 24, 2022
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.